Skip to main content
Erschienen in: Journal of Echocardiography 2/2021

04.03.2021 | Review Article

Combination of echocardiography and emergency endomyocardial biopsy for suspected myocarditis in the cardiovascular emergency medical care

verfasst von: Hirohide Matsuura, Nozomi Watanabe, Yoshisato Shibata, Yujiro Asada

Erschienen in: Journal of Echocardiography | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Myocarditis is a fatal inflammatory disease of myocardium, diagnosed with clinical and histopathological findings by endomyocardial biopsy (EMB). Myocarditis has a variety of clinical presentations and a dynamic and sometimes rapid process of severity. Echocardiography plays an important role in the management of myocarditis because it has noninvasiveness and portability. Once acute myocarditis is suspected by an echocardiography, pathological information should be required as early as possible. In our cardiovascular center, emergency EMB suspecting myocarditis was performed in 19 cases (1.3%) among consecutive 1469 cases (70.1 ± 12.6 years old, male 67.5%) undergoing emergency coronary angiograms from April 2014 to September 2017. Hematoxylin–eosin stain of the biopsy specimens were prepared with microwave-accelerated histoprocessing within 3–5 hours after EMB for rapid pathological diagnosis of myocarditis. We reviewed the value of emergency echo-EMB combination leading to the early decision making of intensive care, corticosteroids and proper mechanical circulatory support prior to the possible sudden collapse in patients with myocarditis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48 (48a-48d).PubMedCrossRef Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48 (48a-48d).PubMedCrossRef
4.
Zurück zum Zitat Pahuja M, Adegbala O, Mishra T, et al. Trends in the incidence of in-hospital mortality, cardiogenic shock, and utilization of mechanical circulatory support devices in myocarditis (analysis of national inpatient sample data, 2005–2014). J Card Fail. 2019;25:457–67.PubMedCrossRef Pahuja M, Adegbala O, Mishra T, et al. Trends in the incidence of in-hospital mortality, cardiogenic shock, and utilization of mechanical circulatory support devices in myocarditis (analysis of national inpatient sample data, 2005–2014). J Card Fail. 2019;25:457–67.PubMedCrossRef
5.
Zurück zum Zitat Ammirati E, Veronese G, Cipriani M, et al. Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment. Curr Cardiol Rep. 2018;20:114.PubMedCrossRef Ammirati E, Veronese G, Cipriani M, et al. Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment. Curr Cardiol Rep. 2018;20:114.PubMedCrossRef
6.
Zurück zum Zitat Ammirati E, Cipriani M, Moro C, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation. 2018;138:1088–99.PubMedCrossRef Ammirati E, Cipriani M, Moro C, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation. 2018;138:1088–99.PubMedCrossRef
7.
Zurück zum Zitat Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158–76.PubMedCrossRef Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158–76.PubMedCrossRef
8.
Zurück zum Zitat Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American heart association. Circulation. 2016;134:e579–646.PubMedCrossRef Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American heart association. Circulation. 2016;134:e579–646.PubMedCrossRef
9.
Zurück zum Zitat Ammirati E, Veronese G, Bottiroli M, et al. Update on acute myocarditis. Trends Cardiovasc Med. 2020. Ammirati E, Veronese G, Bottiroli M, et al. Update on acute myocarditis. Trends Cardiovasc Med. 2020.
10.
Zurück zum Zitat Kociol RD, Cooper LT, Fang JC, et al. Recognition and Initial management of fulminant myocarditis: a scientific statement from the American heart association. Circulation. 2020;141:e69–92.PubMedCrossRef Kociol RD, Cooper LT, Fang JC, et al. Recognition and Initial management of fulminant myocarditis: a scientific statement from the American heart association. Circulation. 2020;141:e69–92.PubMedCrossRef
11.
Zurück zum Zitat Pinamonti B, Alberti E, Cigalotto A, et al. Echocardiographic findings in myocarditis. Am J Cardiol. 1988;62:285–91.PubMedCrossRef Pinamonti B, Alberti E, Cigalotto A, et al. Echocardiographic findings in myocarditis. Am J Cardiol. 1988;62:285–91.PubMedCrossRef
12.
Zurück zum Zitat Skouri HN, Dec GW, Friedrich MG, et al. Noninvasive imaging in myocarditis. J Am Coll Cardiol. 2006;48:2085–93.PubMedCrossRef Skouri HN, Dec GW, Friedrich MG, et al. Noninvasive imaging in myocarditis. J Am Coll Cardiol. 2006;48:2085–93.PubMedCrossRef
14.
Zurück zum Zitat Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21:245–74.PubMedCrossRef Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21:245–74.PubMedCrossRef
15.
Zurück zum Zitat Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–33.PubMedCrossRef Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–33.PubMedCrossRef
16.
Zurück zum Zitat Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J. 2007;28:1242–9.PubMedCrossRef Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J. 2007;28:1242–9.PubMedCrossRef
17.
Zurück zum Zitat Ammirati E, Moroni F, Sormani P, et al. Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. Int J Cardiol. 2017;231:216–21.PubMedCrossRef Ammirati E, Moroni F, Sormani P, et al. Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. Int J Cardiol. 2017;231:216–21.PubMedCrossRef
18.
Zurück zum Zitat Lagan J, Schmitt M, Miller CA. Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases. Int J Cardiovasc Imaging. 2018;34(1):35–54.PubMedCrossRef Lagan J, Schmitt M, Miller CA. Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases. Int J Cardiovasc Imaging. 2018;34(1):35–54.PubMedCrossRef
19.
Zurück zum Zitat Francone M, Chimenti C, Galea N, et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging. 2014;7:254–63.PubMedCrossRef Francone M, Chimenti C, Galea N, et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging. 2014;7:254–63.PubMedCrossRef
20.
Zurück zum Zitat Veronese G, Ammirati E, Cipriani M, et al. Fulminant myocarditis: characteristics, treatment, and outcomes. Anatol J Cardiol. 2018;19:279–86.PubMedPubMedCentral Veronese G, Ammirati E, Cipriani M, et al. Fulminant myocarditis: characteristics, treatment, and outcomes. Anatol J Cardiol. 2018;19:279–86.PubMedPubMedCentral
21.
Zurück zum Zitat Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997;95:163–8.PubMedCrossRef Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997;95:163–8.PubMedCrossRef
22.
Zurück zum Zitat Gilotra NA, Minkove N, Bennett MK, et al. Lack of relationship between serum cardiac troponin I level and giant cell myocarditis diagnosis and outcomes. J Card Fail. 2016;22:583–5.PubMedCrossRef Gilotra NA, Minkove N, Bennett MK, et al. Lack of relationship between serum cardiac troponin I level and giant cell myocarditis diagnosis and outcomes. J Card Fail. 2016;22:583–5.PubMedCrossRef
23.
Zurück zum Zitat Mason JW, O’Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–75.PubMedCrossRef Mason JW, O’Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–75.PubMedCrossRef
24.
Zurück zum Zitat Jani SM, Nallamothu BK, Cooper LT, et al. Beating, fast and slow. N Engl J Med. 2017;377:72–8.PubMedCrossRef Jani SM, Nallamothu BK, Cooper LT, et al. Beating, fast and slow. N Engl J Med. 2017;377:72–8.PubMedCrossRef
25.
Zurück zum Zitat Ammirati E, Cipriani M, Lilliu M, et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation. 2017;136:529–45.PubMedCrossRef Ammirati E, Cipriani M, Lilliu M, et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation. 2017;136:529–45.PubMedCrossRef
26.
Zurück zum Zitat Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J. 2002;66:133–44.PubMedCrossRef Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J. 2002;66:133–44.PubMedCrossRef
27.
Zurück zum Zitat Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience. Eur J Cardiothorac Surg. 2011;40:682–8.PubMed Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience. Eur J Cardiothorac Surg. 2011;40:682–8.PubMed
28.
Zurück zum Zitat Diddle JW, Almodovar MC, Rajagopal SK, et al. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med. 2015;43:1016–25.PubMedCrossRef Diddle JW, Almodovar MC, Rajagopal SK, et al. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med. 2015;43:1016–25.PubMedCrossRef
29.
Zurück zum Zitat Lorusso R, Centofanti P, Gelsomino S, et al. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5-year multi-institutional experience. Ann Thorac Surg. 2016;101:919–26.PubMedCrossRef Lorusso R, Centofanti P, Gelsomino S, et al. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5-year multi-institutional experience. Ann Thorac Surg. 2016;101:919–26.PubMedCrossRef
30.
Zurück zum Zitat Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nat Rev Cardiol. 2016;13:481–92.PubMedCrossRef Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nat Rev Cardiol. 2016;13:481–92.PubMedCrossRef
31.
Zurück zum Zitat Schubert S, Opgen-Rhein B, Boehne M, et al. Severe heart failure and the need for mechanical circulatory support and heart transplantation in pediatric patients with myocarditis: results from the prospective multicenter registry “MYKKE.” Pediatr Transplant. 2019;23:e13548.PubMedCrossRef Schubert S, Opgen-Rhein B, Boehne M, et al. Severe heart failure and the need for mechanical circulatory support and heart transplantation in pediatric patients with myocarditis: results from the prospective multicenter registry “MYKKE.” Pediatr Transplant. 2019;23:e13548.PubMedCrossRef
32.
Zurück zum Zitat Meani P, Gelsomino S, Natour E, et al. Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature. Eur J Heart Fail. 2017;19:84–91.PubMedCrossRef Meani P, Gelsomino S, Natour E, et al. Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature. Eur J Heart Fail. 2017;19:84–91.PubMedCrossRef
33.
Zurück zum Zitat Luyt CE, Hékimian G, Ginsberg F. What’s new in myocarditis? Intensive Care Med. 2016;42:1055–7.PubMedCrossRef Luyt CE, Hékimian G, Ginsberg F. What’s new in myocarditis? Intensive Care Med. 2016;42:1055–7.PubMedCrossRef
34.
Zurück zum Zitat Heymans S, Eriksson U, Lehtonen J, et al. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:2348–64.PubMedCrossRef Heymans S, Eriksson U, Lehtonen J, et al. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:2348–64.PubMedCrossRef
35.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.PubMedCrossRef Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.PubMedCrossRef
36.
Zurück zum Zitat Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70:2363–75.PubMedCrossRef Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70:2363–75.PubMedCrossRef
37.
Zurück zum Zitat Ammirati E, Stucchi M, Brambatti M, et al. Eosinophilic myocarditis: a paraneoplastic event. Lancet. 2015;385:2546.PubMedCrossRef Ammirati E, Stucchi M, Brambatti M, et al. Eosinophilic myocarditis: a paraneoplastic event. Lancet. 2015;385:2546.PubMedCrossRef
38.
Zurück zum Zitat Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45.PubMedCrossRef Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45.PubMedCrossRef
39.
Zurück zum Zitat Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995–2002.PubMedCrossRef Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995–2002.PubMedCrossRef
41.
42.
43.
Zurück zum Zitat Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–64.PubMedPubMedCentralCrossRef Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–64.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9:e013757.PubMedPubMedCentralCrossRef Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9:e013757.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68.PubMedCrossRef Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68.PubMedCrossRef
Metadaten
Titel
Combination of echocardiography and emergency endomyocardial biopsy for suspected myocarditis in the cardiovascular emergency medical care
verfasst von
Hirohide Matsuura
Nozomi Watanabe
Yoshisato Shibata
Yujiro Asada
Publikationsdatum
04.03.2021
Verlag
Springer Singapore
Erschienen in
Journal of Echocardiography / Ausgabe 2/2021
Print ISSN: 1349-0222
Elektronische ISSN: 1880-344X
DOI
https://doi.org/10.1007/s12574-021-00521-0

Weitere Artikel der Ausgabe 2/2021

Journal of Echocardiography 2/2021 Zur Ausgabe

Case image in cardiovascular ultrasound

Interaction between VA-ECMO and Impella

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.